[
  {
    "section": "CraigE.Gordon,GaelenAdam,MarcelloA.Tonelli,MichaelCheung,AmyEarleyandBradH.Rovin (Part 1)",
    "content": "12\nDivisionofNephrology,UniversityHospital,Rheinisch-WestfälischeTechnischeHochschule(RWTH)Aachen,Aachen,Germany;Division\nofExperimentalMedicine&Immunotherapeutics,SchoolofClinicalMedicine,UniversityofCambridge,Cambridge,UK;Divisionof\nNephrology,DepartmentofInternalMedicine,UniversityofGroningen,Groningen,TheNetherlands;DepartmentofNephrology,1st\nFacultyofMedicineandGeneralUniversityHospital,CharlesUniversity,Prague,CzechRepublic;CenterforEvidenceSynthesisinHealth,\nBrownUniversitySchoolofPublicHealth,Providence,RhodeIsland,USA;DivisionofNephrology,TuftsMedicalCenter,Boston,\n78\nMassachusetts,USA;DepartmentofMedicine,CummingSchoolofMedicine,UniversityofCalgary,Calgary,Alberta,Canada;KDIGO,\nBrussels,Belgium;andDepartmentofInternalMedicine,TheOhioStateUniversityCollegeofMedicine,Columbus,Ohio,USA\nIn2021,theKidneyDisease:ImprovingGlobalOutcomesn2021,amajorrevisionoftheKidneyDisease:Improving\nGlobalOutcomes(KDIGO)ClinicalPracticeGuidelinefor\n(KDIGO)GuidelinefortheManagementofGlomerular\nDiseaseswaspublished.KDIGOiscommittedtoprovidingtheManagementofGlomerularDiseaseswaspublished. Sincepublication,importantdataconcerninganti-\nthenephrologycommunitywithperiodicupdates,based\nneutrophilcytoplasmicantibody(ANCA)associatedvascu-\nonnewdevelopmentsforeachdisease.Forpatientswith\nanti-neutrophilcytoplasmicantibody(ANCA)associatedlitis(AAV)havebecomeavailable,promptingthisguideline\nupdate.Probablythemostsignicantdevelopmenthasbeen\nvasculitis(AAV),avacopanreceivedregulatoryapprovalin\ntheapprovaloftheC5areceptorinhibitoravacopanbythe\nlate2021,leadingtothisKDIGOguidelineupdate.In\nUnitedStatesFoodandDrugAdministration(FDA)andthe\naddition,theevidencesupportingalower-dose\nglucocorticoidinductionregimenorevencompleteEuropeanMedicinesAgency(EMA)asadd-ontherapyto\n2,3\nstandard-of-careforthetreatmentofAAV.Thisdevelop-\nreplacementofglucocorticoidshasbecomestronger. Herein,anexecutivesummaryofthemostimportantmentdirectlyrelatestothesecondmajoremergingnovel\napproachtothetreatmentofAAV,namely,areductionof\nguidelinechangesfromtheAAVchapterisprovidedasa\nsystemicglucocorticoidexposure.Althoughthelatteris\nquickreference. obviouslydesirable,giventheshort-andlong-termcompli-\nKidneyInternational\n(2024)105,447–449;https://doi.org/10.1016/\ncationsofglucocorticoids,itislessclearwhichpatientsneed\nj.kint.2023.10.009\navacopaninordertoallowforlowerglucocorticoiddosages. KEYWORDS:ANCA-associatedvasculitis;glomerulardiseases;glomerulone-\nphritis;guideline;KDIGO;systematicreview\nAtthesametime,thisnewtherapyaddssignicantcostto\nCopyright2023,KidneyDisease:ImprovingGlobalOutcomes(KDIGO). treatment,andlong-termsafetydataarecurrentlylacking. PublishedbyElsevierInc.onbehalfoftheInternationalSocietyof\nThisExecutiveSummaryprovidesabriefsnapshotofthe\nNephrology.ThisisanopenaccessarticleundertheCCBY-NC-ND\nupdatedguideline,butreadersareencouragedtoviewthefull\nlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/).",
    "page": 1,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "CraigE.Gordon,GaelenAdam,MarcelloA.Tonelli,MichaelCheung,AmyEarleyandBradH.Rovin (Part 2)",
    "content": "chapterfordetaileddiscussionandusefulpracticepoints\n(SupplementaryTableS1;https://kdigo.org/guidelines/gd/). Nomajorchangeshavebeenmadeinsectionsrelatedto\ndiagnosisandassessmentofprognosisofAAV(https://kdigo. org/guidelines/gd/).ThemostimportantupdateintheANCA\nguidelinerelatestoinductiontherapy.Recommendation\n9.3.1.1,Werecommendthatglucocorticoidsincombina-\ntionwithcyclophosphamideorrituximabbeusedasinitial\ntreatmentofnew-onsetAAV(1B),didnotchange,butthe\nCorrespondence:JürgenFloege,DivisionofNephrology,RWTHAachen\ndiscussionnowplacesstrongeremphasisonamorerapid\nUniversityHospital,Pauwelsstrasse30,Aachen52074,Germany.E-mail:\nreductionofglucocorticoiddose,basedontherecentLow-\njoege@ukaachen.de\nDoseGlucocorticoidVasculitisInductionStudy(LoVAS),\nThecompleteKDIGO2024ClinicalPracticeGuidelinefortheManagement\namongothers.ThestudyrandomizedpatientswithAAVto\nofAntineutrophilCytoplasmicAntibody(ANCA)AssociatedVasculitisis\nreceivereduced-doseprednisolone(0.5mg/kg/d)orhigh-\npublishedinKidneyInternational,volume105,issue3S,2024,whichis\ndoseprednisolone(1mg/kg/d)plus4dosesof375mg/m/\navailableonlineatwww.kidney-international.org. wkrituximab.Reduced-doseglucocorticoidsledtoasimilar\nReceived11September2023;revised20October2023;accepted20\nremissionrate,butthefrequencyofsevereinfectionswas\nOctober2023\nKidneyInternational\n447\n(2024)105,447–449\nKDIGOexecutiveconclusions\nJFloegeetal.:ExecutivesummaryofKDIGO2024AAVGuideline\nDiagnosis of AAV\nDisease assessment\nInduction of remission\nNo organ-threateningVital organ/life-threatening\ninvolvementSerum creatinine >3.4 mg/dl (>300 µmol/l)\nRituximab + cyclophosphamideCyclophosphamide +Rituximab +\nOR (glucocorticoid taper(glucocorticoid taper\nCyclophosphamide +\nOR avacopan)OR avacopan)\n(glucocorticoid taper OR avacopan)\nConsider plasma exchange\nDisease control\n‘on drug’ remission\nMaintenance\nSwitch to azathioprineContinue\nTaper glucocorticoidsrituximab\nTaperStop\nazathioprinerituximab\nFigure1|Practicaltreatmentregimenforantineutrophilcytoplasmicantibodyassociatedvasculitis(AAV).",
    "page": 1,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "CraigE.Gordon,GaelenAdam,MarcelloA.Tonelli,MichaelCheung,AmyEarleyandBradH.Rovin (Part 3)",
    "content": "reduced.Alimitationofthestudyisthatitincludedonlyremissionandsevereadverseeventswasgradedasmoderate,\nJapanesepatientswithpredominantlymyeloperoxidasebutthecertaintyofevidenceforinfectionsanddiscontinua-\n(MPO)-ANCA-associatedvasculitis.Nonetheless,thesedatationduetoadverseeventsweregradedaslow.TheWork\n“”\nsupportthereduced-glucocorticoiddoseasusedintheGroupconsideredtheresultsofbothrandomizedcontrolled\nPlasmaExchangeandGlucocorticoidsfortheTreatmentoftrials(RCTs)whendecidingtomakeavacopanapractice\nANCA-AssociatedVasculitis(PEXIVAS)trial.pointratherthanarecommendation.Patientswithan\nThemostimportantchangeinAAVinductiontherapyisincreasedriskofglucocorticoidtoxicityarelikelytobenet\nposthoc\ntheavailabilityofavacopanforAAV(Figure1;PracticePointmostfromavacopan.Furthermore,aanalysisof\nﬁ<\n9.3.1.1andPracticePoint9.3.1.7inguideline).Twopatientswithlowglomerularltrationrate(GFR)(30ml/\nplacebo-controlledrandomizedcontrolledtrials(RCTs)minper1.73m)suggestedgreaterGFRrecoverywithava-\nstudiedavacopaninAAV;oneoftheRCTs(APhase3Clinicalcopanascomparedtoglucocorticoidtherapy. TrialofCCX168[Avacopan]inPatientswithANCA-Controversystillsurroundsthevalueofplasmaexchangein\nAssociatedVasculitis[ADVOCATE])hadnoseriousmeth-AAVpatientswithasevereclinicalcourse.FromthePublic\nodologicalconcerns,buttheotherRCT(ClinicalANCAReview,approvalforPracticePoint9.3.1.9.wasrelativelylow,at\nﬁ“\nVasculitisSafetyandEfcacyStudyofInhibitorofC5aR75%:Considerplasmaexchangeforpatientswithserum\napriori>>\n[CLASSIC])hadahighdropoutrateandchangedthecreatinine(SCr)3.4mg/dl(300mol/l),patientsrequiring\nprimaryoutcome.ThecertaintyoftheevidenceforsustaineddialysisorwithrapidlyincreasingSCr,andpatientswithdiffuse\nKidneyInternational\n448\n(2024)105,447–449",
    "page": 1,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "KDIGOexecutiveconclusions",
    "content": "JFloegeetal.:ExecutivesummaryofKDIGO2024AAVGuideline\nJFreportsreceivingconsultancyfeesand/orspeakerhonoraria",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "alveolarhemorrhagewhohavehypoxemia.However,a2022",
    "content": "fromAstraZeneca,Bayer,Calliditas,Chinook,GlaxoSmithKline,",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "meta-analysisconcludedthatthereisareductionofkidney",
    "content": "Novartis,Omeros,Otsuka,Stadapharm,andTravere;andservingon",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "failureat12monthswithplasmaexchange,withnoevidenceof",
    "content": "datasafetymonitoringboardsforNovoNordiskandVisterra.DRWJ",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "seriousinfections.Atpresent,theroutineuseofplasmaex-",
    "content": "GlaxoSmithKline,Novartis,Takeda,andVifor;grant/researchsupport",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "changeisnotrecommendedforpatientspresentingwitha",
    "content": "fromGlaxoSmithKline*,Roche*,andVifor*;fundingforlectures,",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "GFR50ml/minper1.73m,butitcanbeconsideredin",
    "content": "presentations,speakersbureaus,manuscriptwritingoreducational",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": ">>",
    "content": "eventsfromOtsukaandVifor;servingonaDataSafetyMonitoring",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "patientswithmoreseverepresentations(SCr3.4mg/dl[300",
    "content": "BoardorAdvisoryBoardforChinookandGlaxoSmithKline;receiving",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "mol/l],especiallyifoliguric)orthosewithalveolarhemor-",
    "content": "fundingsupportforaleadershiporduciaryroleatAurinia;and",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "rhageandhypoxemia,inwhomearlymortalityishigh.Plasma",
    "content": "receivingstockorstockoptionsfromAurinia.VTreportsreceiving",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "exchangeshouldbeusedinpatientswithconcomitantanti-",
    "content": "fundingforaleadershiporduciaryroleatCalliditas,Novartis,",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "glomerularbasementmembrane(GBM)disease.Conversely,",
    "content": "Omeros,Otsuka,andTravere.CEGreportsreceivingconsultancyfees",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "plasmaexchangeisnotrequiredfortherapyofdiffusealveolar",
    "content": "fromAlexion;servingonthespeakerbureauforAlexion;and",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "hemorrhageintheabsenceofhypoxemia.",
    "content": "receivingfundingfortraveland/oraccommodationfromAlexion.\nMATreportsreceivingpaymentforexperttestimonyfromGilead",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "Maintenancetherapyhasnotchangedinthe2024guide-",
    "content": "Sciences(notrelatedtotheguidelinetopic).BHRreportsreceiving",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "lineupdate,andRecommendation9.3.2.1stillstatesWe",
    "content": "consultancyfeesfromAlexion,AstraZeneca,Aurinia,BristolMyers",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "recommendmaintenancetherapywitheitherrituximab,or",
    "content": "Squibb,Exagen,Genentech,GlaxoSmithKline,KezarLifeSciences,",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "azathioprineandlow-doseglucocorticoidsafterinduction",
    "content": "Kyverna,Novartis,andOtsuka;andgrant/researchsupportfrom",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "ofremission(1C).Forbothazathioprineandrituximab,the",
    "content": "Biogen*.Alltheotherauthorsdeclarednocompetinginterests.",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "and/orANCA,butdosingbasedonBcellcountsledtofewer",
    "content": "SupplementaryTableS1.Comparisonofthe2021and2024KDIGO\n10,11",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "infusionsandthuslowercost.",
    "content": "ClinicalPracticeGuidelinefortheManagementofAntineutrophil",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "neyfailure,anti-MPOpositivity,andnoextrarenalsymptoms,",
    "content": "1.KidneyDisease:ImprovingGlobalOutcomes(KDIGO)Glomerular",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "long-termmaintenancemaynotbenecessary.Inthissituation,",
    "content": "DiseasesWorkGroup.KDIGO2021clinicalpracticeguidelineforthe\nmanagementofglomerulardiseases.KidneyInt.2021;100(4S):S1S276.",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "theneedfor(andlengthof)maintenancetreatmentshouldbe",
    "content": "2.EuropeanMedicinesAgency.First-in-classmedicinerecommendedfor",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "assessedatanindividuallevel.",
    "content": "treatmentofrarebloodvesselinammation.AccessedSeptember11,",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "Thereisnonewinformationtoguideclinicalapproachestoﬁ",
    "content": "2023.https://www.ema.europa.eu/en/news/rst-class-medicine-\nrecommended-treatment-rare-blood-vessel-inammation",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "AAVinpatientswithrelapsingorrefractorydisease,orafter",
    "content": "3.USFoodandDrugAdministration.FDAapprovesadd-ondrugforadults",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "kidneytransplantation;thus,thecontentofthe2021guideline",
    "content": "withrareformofbloodvesselinammation.AccessedSeptember11,",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "didnotchange.Finally,researchrecommendationsfromthis",
    "content": "2023.https://www.fda.gov/drugs/news-events-human-drugs/fda-\napproves-add-drug-adults-rare-form-blood-vessel-inammation",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "2024guidelinestillcallforRCTsthatincorporatepatient-",
    "content": "4.FurutaS,NakagomiD,KobayashiY,etal.Effectofreduced-dosevshigh-",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "reportedoutcomes,moreprolongedlong-termoutcome",
    "content": "doseglucocorticoidsaddedtorituximabonremissioninductionin",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "studies,studiesaimedatdeningtheroleofrituximabinse-",
    "content": "ANCA-associatedvasculitis:arandomizedclinicaltrial.JAMA.2021;325:\n21782187.",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "ulations.Anotherareainwhichthereisalargeunmetneedis",
    "content": "glucocorticoidsinsevereANCA-associatedvasculitis.NEnglJMed.",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "theidenticationofbiomarkerstobetterguidetreatment.–",
    "content": "2020;382:622631.\n6.JayneDRW,MerkelPA,SchallTJ,etal.Avacopanforthetreatmentof",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "Hopefully,thesefuturetrials,ifsuccessful,willleadtoyet",
    "content": "ANCA-associatedvasculitis.NEnglJMed.2021;384:599609.",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  },
  {
    "section": "anotherupdateoftheKDIGOAAVguidelineinthenear-term.",
    "content": "7.MerkelPA,NilesJ,JimenezR,etal.Adjunctivetreatmentwithavacopan,\nanoralC5areceptorinhibitor,inpatientswithantineutrophilcytoplasmic\nantibody-associatedvasculitis.ACROpenRheumatol.2020;2:662671.\nDISCLOSURE\n8.CortazarFB,NilesJL,JayneDRW,etal.Renalrecoveryforpatientswith\nThedevelopmentandpublicationofthisguidelineweresupportedby\nANCA-associatedvasculitisandloweGFRintheADVOCATEtrialof\nKidneyDisease:ImprovingGlobalOutcomes(KDIGO).Theopinionsor\navacopan.KidneyIntRep.2023;8:860870.\nviewsexpressedinthissummaryarethoseoftheauthorsanddonot\n9.WalshM,CollisterD,ZengL,etal.Theeffectsofplasmaexchangein\nnecessarilyreecttheopinionsorrecommendationsofthe\npatientswithANCA-associatedvasculitis:anupdatedsystematicreview\nInternationalSocietyofNephrologyorElsevier.Dosages,indications,\nandmeta-analysis.BMJ.2022;376:e064604.\n10.CharlesP,TerrierB,PerrodeauE,etal.Comparisonofindividually\nandmethodsofuseforproductsthatarereferredtointhesupplement\ntailoredversusxed-schedulerituximabregimentomaintainANCA-\nbytheauthorsmayreecttheirclinicalexperienceormaybederived\nassociatedvasculitisremission:resultsofamulticentre,randomised\nfromtheprofessionalliteratureorotherclinicalsources.Becauseofthe\ncontrolled,phaseIIItrial(MAINRITSAN2).AnnRheumDis.2018;77:\ndifferencesbetweeninvitroandinvivosystemsandbetween\n11431149.\nlaboratoryanimalmodelsandclinicaldatainhumans,invitroand\n11.WaltersGD,WillisNS,CooperTE,etal.Interventionsforrenalvasculitisin\nanimaldatadonotnecessarilycorrelatewithclinicalresults.\nadults.CochraneDatabaseSystRev.2020;1:CD003232.\nKidneyInternational\n449\n(2024)105,447–449",
    "page": 3,
    "source": "KDIGO-2024-ANCA-Vasculitis-Guideline-Executive-Summary.pdf"
  }
]